Therefore, we conclude that the addition of S‐100B measurement in the follow‐up of stage III melanoma prompted detection of stage IV disease in 10% of all asymptomatic stage III patients, and resulted in 23% additional upstaging. This evidence concerns the gene S100B and melanoma.